One line to note in the announcement is :
The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidate’s existing Fast Track designation. If approved, remestemcel-L is planned to be launched in the US in 2020.
That could mean next week or the week after even ? Doesn't necessarily mean we will have to wait the entire month of January IMO
GLTAH
-
- There are more pages in this discussion • 22,741 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.59 |
Change
-0.025(1.55%) |
Mkt cap ! $2.031B | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.62 | $1.57 | $6.345M | 3.987M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 44493 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 4159 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |